Tavulus Glenmark launches Tavulus for COPD treatment in Spain
Mumbai/UNI: Pharma major Glenmark Pharma Monday announced the launch of a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name Tavulus in Spain for the treatment of chronic obstructive pulmonary disease (COPD).
COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissues and narrow airways all of which makes breathing difficult. Studies show that close to 2.5 million people suffer from COPD in Spain, the pharma company release said.
Tavulus is expected to provide relief to a large lung patient population in the country.
It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs and also works to prevent sudden, short-term worsening of COPD symptoms.
Commenting on the launch, Vice President - Business Development of Glenmark Pharmaceuticals Limited, Dr Jiri Havranek, said, “The goal of COPD treatment has always been to provide quick symptomatic relief to patients and reduce the risk of exacerbations. Since its launch, we have seen the multiple therapeutic benefits of Tavulus in other markets, and we are pleased to extend these benefits to patients in Spain."
"This inhalation therapy has been shown to significantly aid in the daily management of COPD. We hope that it improves both COPD symptoms and quality of life in those who are most affected,'' he said.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
